[Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study].

Hong Liu, Guangsheng He, Depei Wu, Aining Sun, Zonghong Shao, Sixuan Qian, Zhijian Xiao, Jun Ma, Shu-ye Wang, Xiao-Ping Xu, Ting Liu, Jie Jin, Zhichao Chen, Meiyun Fang, Baoan Chen, Lan‐Ping Xu, Zhixiang Shen, Changgeng RuanPubMed 2012

Abstract

HAG regimen provides higher CR rate and OR rate for patients with high-risk MDS.
BibTeX
@inproceedings{liu2012clinical,
  author = {Hong Liu and Guangsheng He and Depei Wu and Aining Sun and Zonghong Shao and Sixuan Qian and Zhijian Xiao and Jun Ma and Shu-ye Wang and Xiao-Ping Xu and Ting Liu and Jie Jin and Zhichao Chen and Meiyun Fang and Baoan Chen and Lan‐Ping Xu and Zhixiang Shen and Changgeng Ruan},
  title = {{[Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study].}},
  booktitle = {PubMed},
  year = {2012},
}

Loading related content...

Figure